Tolerance develops in spinal cord, but not in brain with chronic [Dmt 1]DALDA treatment

British Journal of Pharmacology

Volumn 143, Issue 8, 2004, Pages 987-993

  Ben, Yong ^a   Smith, Andrew P ^b   Schiller, Peter W ^b   Lee, Nancy M ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Dmt 1 DALDA; DAMGO; Gene expression; Morphine; Spinal cord; Tolerance

Indexed keywords

COMPLEMENTARY DNA; DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALOXONE; PREPRODYNORPHIN; PREPROENKEPHALIN; PROOPIOMELANOCORTIN; RNA; TYROSYL DEXTRO ARGINYLPHENYLALANYLLYSINAMIDE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BRAIN; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG CROSS TOLERANCE; DRUG DEPENDENCE; DRUG EFFECT; DRUG TOLERANCE; GENE EXPRESSION; LONG TERM CARE; MALE; MORPHINE TOLERANCE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PAIN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SPINAL CORD; TAIL FLICK TEST;

ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; MALE; MICE; MICE, INBRED ICR; OLIGOPEPTIDES; PAIN MEASUREMENT; SPINAL CORD; TYROSINE;

EID: 11244271472     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706007     Document Type: Article

References (26)

1. BESSE, D., LOMBARD, M.C. & BESSON, J.M. (1992). Up-regulation of [3H]DAMGO and [3H]DTLET opioid binding sites in laminae I-II of the spinal cord in intact and deafferented morphine-tolerant animals. Neurosci. Lett., 136, 209-212.
2. BROCCARDO, M., ERSPAMER, V., FALCONIERI-ESPAMER, G., IMPROTA, G., LINARI, G., MELCHIORRI, P. & MONTENUCCHI, P.C. (1981). Pharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skin. Br. J. Pharmacol., 73, 625-631.
3. BRODSKY, M., ELLIOTT, K., HYANKSY, A. & INTURRISI, C.E. (1995). CNS levels of Mu opioid receptor (MOR-1) mRNA during chronic treatment with morphine or naltrexone. Brain Res. Bull., 38, 135-141.
4. BUZAS, B., ROSENBERGER, J. & COX, B.M. (1996). Mu and delta opioid receptor gene expression after chronic treatment with opioid agonist. Neuroreport. 7, 1505-1508.
5. FANG, Y., KELLY, M.J. & RONNEKLEIV, O.K. (1998). Proopiomelanocortin (POMC) mRNA expression: distribution and region-specific down-regulation by chronic morphine in female guinea pig hypothalamus. Brain Res. Mol. Brain Res., 55, 1-8.
6. GUDEHITHLU, K.P. & BHARGAVA, H.N. (1995). Modulation of preproenkephalin mRNA levels in brain regions and spinal cord of rats treated chronically with morphine. Peptides, 16, 415-419.
7. HOOKE, L.P., HE, L. & LEE, N.M. (1995). Dynorphin A modulates acute and chronic opioid effects. J. Pharmacol. Exp. Ther., 273, 292-297.
8. HYLDEN, J.L.K. & WILCOX, G. (1980). Intrathecal morphine in mice: a new technique. Eur. J. Pharmacol., 67, 313-316.
9. KEST, B., JENAB, S., BRODSKY, M., ELLIOTT, K. & INTURRISI, C.E. (1994). Supraspinal delta opioid receptor mRNA levels are not altered in [D-Ala2]deltorphin II tolerant mice. J. Neurosci. Res., 39, 674-679.
10. LITCHFIELD JR, J.T. & WILCOXON, R. (1949). A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther., 96, 99-113.
11. MIGLECZ, E., SZEKELY, J.L. & DUNAI-KOVACS, Z. (1979). Comparison of tolerance development and dependence capacities of morphine, beta-endorphin, and [D-Met2, Pro5]-enkephalinamide. Psychopharmacology, 62, 29-34.
12. MOCCHETTI, I., RITTER, A. & COSTA, E. (1989). Down-regulation of proopiomelanocortin synthesis and beta-endorphin utilization in hypothalamus of morphine-tolerant rats. J. Mol. Neurosci., 1, 33-38.
13. NEILAN, C.L., NGUYEN, T.M., SCHILLER, P.W. & PASTERNAK, G.W. (2001). Pharmacological characterization of the dermorphin analog [Dmt1]DALDA, a highly potent and selective mu-opioid peptide. Eur. J. Pharmacol., 419, 15-23.
14. NYLANDER, I., VLASKOVSKA, M. & TERENIUS, L. (1995). The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-Dawley rats. Psychopharmacology, 118, 391-400.
15. POLASTRON, J., MEUNIER, J.C. & JAUZAC, P. (1994). Chronic morphine induces tolerance and desensitization of mu-opioid receptor but not down-regulation in rabbit. Eur. J. Pharmacol., 266, 139-146.
16. RIBA, P., BEN, Y., NGUYEN, T.M.-D., FURST, S., SCHILLER, P.W. & LEE, N.M. (2002a). [Dmt1]DALDA is highly selective and potent at μ opioid receptors, but is not cross-tolerant with systemic morphine. Curr. Med. Chem., 9, 31-39.
17. RIBA, P., BEN, Y., SMITH, A.P., FURST, S. & LEE, N.M. (2002b). Morphine tolerance in spinal cord is due to interaction between mu- and delta-receptors. J. Pharmacol. Exp. Ther., 300, 265-272.
18. SCHILLER, P.W., NGUYEN, T.M.-D., BEREZOWSKA, I., DUPUIS, S., WELTROWSKA, G., CHUNG, N.N. & LEMIEUX, C. (2000). Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur. J. Med. Chem., 35, 895-901.
19. TJON, G.H., VOORN, P., VANDERSCHUREN, L.J., DE VRIES, T.J., MICHIELS, N.H., JONKER, A.J., KLOP, H., NESTBY, P., MULDER, A.H. & SCHOFFELMEER, A.N. (1997). Delayed occurrence of enhanced striatal preprodynorphin gene expression in behaviorally sensitized rats: differential long-term effects of intermittent and chronic morphine administration. Neuroscience, 76, 167-176.
20. TRUJILLO, K.A. & AKIL, H. (1995). Excitatory amino acids and drugs of abuse: a role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence. Drug Alcohol Depend., 38, 139-154.
21. TULUNAY, F.C. & TAKEMORI, A.E. (1974). The increased efficacy of narcotic antagonists induced by various anarcotic analgesics. J. Pharmacol. Exp. Ther., 190, 395-400.
22. TURCHAN, J., LASON, W., BUDZISZEWSKA, B. & PRZEWLOCKA, B. (1997). Effects of single and repeated morphine administration on the prodynorphin, proenkephalin and dopamine D2 receptor gene expression in the mouse brain. Neuropeptides, 31, 24-28.
23. UNTERWALD, E.M., RUBENFELD, J.M., IMAI, Y., WANG, J.B., UHL, G.R. & KREEK, M.J. (1995). Chronic opioid antagonist administration upregulates mu opioid receptor binging without altering mu opioid receptor mRNA levels. Mol. Brain Res., 33, 351-355.
24. WAY, E.L., LOH, H.H. & SHEN, F. (1968). Morphine tolerance, physical dependence, and synthesis of brain 5-hydroxytryptamine. Science, 162, 1290-1292.
25. WAY, E.L., LOH, H.H. & SHEN, F.-H. (1969). Simultaneous quantitative assessment of morphine tolerance and physical dependence. J. Pharmacol. Exp. Ther., 167, 1-8.
26. ZHAO, G.M., WU, D.L., SOONG, Y., SHIMOYAMA, M., BEREZOWAKA, I., SCHILLER, P.W. & SZETO, H.H. (2002). Profound spinal tolerance after repeated exposure to a highly selective mu-opioid peptide agonist: role of delta-opioid receptors. J. Pharmacol. Exp. Ther., 302, 188-196.